Bernard Spier, MD
Ophthalmology · South Orange, NJNPI 1871578468
Payments from drug & device makers
Across 178 payments — averaging $34.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Glaukos Corporation$2K
- Alcon$716
- Johnson & Johnson Surgical Vision, Inc.$253
- Sight Sciences, Inc.$198
- Biotissue Holdings Inc.$194
- plus $1K from 18 others
What the payments were for
- Food & beverage$5,22486%
- Education$83014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,754 |
| Glaukos Corporation | 14 | $1,727 |
| Alcon | 21 | $716 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $253 |
| Sight Sciences, Inc. | 7 | $198 |
| Biotissue Holdings Inc. | 10 | $194 |
| NEW World Medical,inc. | 1 | $170 |
| Bausch & Lomb Americas Inc. | 3 | $154 |
| Rxsight Inc | 2 | $127 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $119 |
| Oyster Point Pharma, Inc. | 7 | $109 |
| Ivantis, Inc | 1 | $92 |
| Novartis | 6 | $85 |
| Kala Pharmaceuticals, Inc. | 5 | $78 |
| Eyevance Pharmaceuticals LLC | 3 | $49 |
| Sun Pharmaceutical Industries Inc. | 3 | $47 |
| Dompe US, Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Shire North American Group Inc | 2 | $29 |
| Merz North America, Inc. | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Photrexa$303
- iDoseTR$281
- iStent inject Trabecular Micro-Bypass Stent System$266
- Clareon$253
- Tecnis IOL$248
- Kahook Dual Blade$170
- Streamline Surgical System$170
- Ahmed Glaucoma Valve$170
- iStent inject W$160
- KXL System$160
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$154
- PHOTREXA CROSS-LINKING KIT$154
- iAccess Precision Blade$154
- iStent$152
- Centurion$144
- iStent infinite Trabecular Micro-Bypass System Model iS3$139
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$139
- iStent Infinite$130
- CATALYS SYSTEM$124
- VYZULTA$120
How this compares
$6,054 in reported general payments places this provider in the 85th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 111 | $48,705 |
| RestasisCyclosporine | 21 | $23,465 |
| CombiganBrimonidine Tartrate/Timolol | 80 | $22,971 |
| XiidraLifitegrast | 20 | $21,476 |
| RocklatanNetarsudil Mesylat/Latanoprost | 38 | $18,672 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 49 | $11,301 |
| Brimonidine Tartrate | 77 | $8,607 |
| Prednisolone Acetate | 175 | $5,454 |
| Timolol Maleate | 210 | $4,524 |
| Ketorolac Tromethamine | 195 | $4,104 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $3,985 |
| Latanoprost | 507 | $3,607 |
| Alphagan PBrimonidine Tartrate | 11 | $3,525 |
| Brinzolamide | 18 | $3,244 |
| Ofloxacin | 142 | $2,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,754 | $98,668223 claims |
| Bausch & Lomb Americas Inc.Xiidra | $154 | $21,47620 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $15 | $18,67238 claims |
| AlconSimbrinza | $716 | $11,30149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in South Orange
- Charles CraneSouth Orange$582K
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.